STUDY | ADMIN | CCADMIN | ACCR. GOAL |
R E G |
O P E N |
ARM | TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol | PEOLC | 491 | 1 | Y | 0 Screening | 375 | 46 | 46 | 25 | 6 | 0 | 11/01/2017 | 240 | 85 | |
375 | 46 | 46 | 25 | 6 | 0 | ||||||||||
2 | Y | 1 Carvedilol | 74 | 0 | 0 | 0 | 0 | 0 | |||||||
2 No prophylaxis | 81 | 0 | 0 | 0 | 0 | 0 | |||||||||
3 Observation | 185 | 30 | 30 | 17 | 4 | 0 | |||||||||
340 | 30 | 30 | 17 | 4 | 0 | ||||||||||
S1703-Met Breast, STM-monitoring v Usual Care | CCD | SXQOL | 739 | 1 | Y | 0 Screening | 597 | 99 | 50 | 29 | 7 | 2 | 09/17/2018 | 201 | 90 |
597 | 99 | 50 | 29 | 7 | 2 | ||||||||||
2 | Y | 1 Control (Usual Care) | 201 | 34 | 17 | 6 | 3 | 0 | |||||||
2 Intervention (STMDDM) | 201 | 31 | 17 | 7 | 2 | 1 | |||||||||
402 | 65 | 34 | 13 | 5 | 1 | ||||||||||
S1802-Pros, Stg IV, SST ± Surg/RT to Primary Tum | GU | SXQOL | 1273 | 1 | Y | 0 Induction SST | 913 | 111 | 50 | 32 | 4 | 1 | 09/24/2018 | 329 | 138 |
913 | 111 | 50 | 32 | 4 | 1 | ||||||||||
2 | Y | 1 Standard Systemic Therapy Only | 329 | 47 | 19 | 9 | 3 | 1 | |||||||
2 SST + Surgery/RT | 323 | 41 | 11 | 3 | 1 | 0 | |||||||||
652 | 88 | 30 | 12 | 4 | 1 | ||||||||||
S1803-MM, Maintenance, Len vs Len/Dara | MMYEL | SXQOL | 1100 | 2 | Y | 1 Lenalidomide | 674 | 102 | 38 | 9 | 1 | 1 | 08/13/2019 | 334 | 127 |
2 Lenalidomide + Daratumumab | 662 | 98 | 36 | 7 | 0 | 0 | |||||||||
1336 | 200 | 74 | 16 | 1 | 1 | ||||||||||
3 | Y | 3 Continue Lenalidomide | 40 | 13 | 8 | 6 | 3 | 0 | |||||||
4 Stop Lenalidomide | 40 | 12 | 6 | 4 | 1 | 1 | |||||||||
5 Continue Lenalidomide + Dara | 93 | 29 | 17 | 13 | 1 | 0 | |||||||||
6 Stop Lenalidomide + Dara | 96 | 32 | 19 | 13 | 2 | 1 | |||||||||
269 | 86 | 50 | 36 | 7 | 2 | ||||||||||
S1827-SCLC, MRI Surveillance +/- PCI | LUNG | SXQOL | 668 | 1 | Y | 1 PCI + MRI brain surveillance | 140 | 31 | 16 | 9 | 3 | 0 | 05/04/2020 | 344 | 128 |
2 MRI brain surveillance | 138 | 28 | 16 | 9 | 2 | 1 | |||||||||
278 | 59 | 32 | 18 | 5 | 1 | ||||||||||
S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP | LYMPH | SXQOL | 422 | 1 | T | 1 CC-486 + R-miniCHOP | 69 | 18 | 7 | 4 | 0 | 0 | 05/25/2021 | 178 | 65 |
2 R-miniCHOP | 67 | 17 | 8 | 4 | 0 | 0 | |||||||||
136 | 35 | 15 | 8 | 0 | 0 | ||||||||||
S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O | LEUK | SXQOL | 247 | 1 | Y | 1 Delayed V-O | 50 | 14 | 9 | 2 | 1 | 0 | 03/02/2021 | 274 | 100 |
2 Early V-O | 96 | 29 | 17 | 10 | 5 | 1 | |||||||||
146 | 43 | 26 | 12 | 6 | 1 | ||||||||||
S2013-I-CHECKIT: ICI toxicity risk prediction study | SXQOL | 3609 | 1 | Y | 1 Observation Arm | 2204 | 120 | 120 | 83 | 23 | 6 | 09/13/2021 | 237 | 123 | |
2204 | 120 | 120 | 83 | 23 | 6 | ||||||||||
S2205-ICE COMPRESS: Reduction of CIPN from Taxanes | SXQOL | 777 | 1 | Y | 1 Cryocompression | 120 | 74 | 37 | 19 | 7 | 2 | 06/06/2023 | 14 | 29 | |
2 Continuous Compression | 119 | 72 | 35 | 21 | 6 | 2 | |||||||||
3 Low Cyclic Compression | 119 | 72 | 35 | 18 | 4 | 2 | |||||||||
358 | 218 | 107 | 58 | 17 | 6 | ||||||||||
S2206-Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva | BREAST | SXQOL | 960 | 1 | Y | 1 Tissue for MammaPrint testing | 513 | 448 | 265 | 162 | 44 | 4 | 11/27/2023 | 368 | 128 |
513 | 448 | 265 | 162 | 44 | 4 | ||||||||||
2 | Y | 2 SOC Chemotherapy | 85 | 79 | 44 | 27 | 6 | 1 | |||||||
3 SOC Chemotherapy + Durvalumab | 82 | 76 | 42 | 24 | 5 | 0 | |||||||||
167 | 155 | 86 | 51 | 11 | 1 | ||||||||||
S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa | LYMPH | SXQOL | 227 | 1 | Y | 1 Tazemetostat (Arm 1) Dose Level 1 | 7 | 4 | 0 | 0 | 0 | 0 | 09/26/2023 | 123 | 34 |
4 Zanubrutinib (Arm 3) Dose Level 1 | 10 | 0 | 0 | 0 | 0 | 0 | |||||||||
5 Zanubrutinib (Arm 3) Dose Level 2 | 10 | 10 | 0 | 0 | 0 | 0 | |||||||||
27 | 14 | 0 | 0 | 0 | 0 | ||||||||||
S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D | MMYEL | SXQOL | 510 | 1 | Y | 1 VRD-R | 28 | 20 | 12 | 7 | 1 | 0 | 10/12/2023 | 269 | 89 |
2 DRD-R | 26 | 18 | 10 | 4 | 1 | 0 | |||||||||
3 DRD-DR | 25 | 18 | 8 | 5 | 1 | 0 | |||||||||
79 | 56 | 30 | 16 | 3 | 0 | ||||||||||
S2212-Breast, TNBC, Neoadj Chemo + Pembro | BREAST | SXQOL | 2400 | 1 | Y | 1 Carbo + Paclitaxel + Pembro -> AC + Pembro | 312 | 239 | 124 | 69 | 19 | 4 | 09/15/2023 | 376 | 145 |
2 Carbo + Docetaxel + Pembro | 318 | 247 | 130 | 71 | 19 | 2 | |||||||||
630 | 486 | 254 | 140 | 38 | 6 | ||||||||||
S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT | MMYEL | SXQOL | 338 | 1 | Y | 0 Induction | 12 | 12 | 7 | 3 | 1 | 1 | 07/01/2024 | 153 | 45 |
12 | 12 | 7 | 3 | 1 | 1 | ||||||||||
2 | Y | 1 Dara-VCD | 3 | 3 | 2 | 2 | 1 | 0 | |||||||
2 Melphalan + ASCT | 3 | 3 | 3 | 1 | 1 | 0 | |||||||||
6 | 6 | 5 | 3 | 2 | 0 | ||||||||||
3 | Y | 3 Dara | 1 | 1 | 1 | 1 | 0 | 0 | |||||||
1 | 1 | 1 | 1 | 0 | 0 | ||||||||||
S2303-Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo | GI | SXQOL | 224 | 1 | Y | 1 Nivolumab + Paclitaxel + Ramucirumab | 15 | 15 | 12 | 8 | 2 | 1 | 06/24/2024 | 257 | 91 |
2 Paclitaxel + Ramucirumab | 16 | 16 | 12 | 7 | 2 | 0 | |||||||||
31 | 31 | 24 | 15 | 4 | 1 | ||||||||||
S2408-Panc Fistula Prevention, Lanreotide | PEOLC | 274 | 1 | Y | 1 Blinded Drug | 2 | 2 | 2 | 2 | 2 | 0 | 05/09/2025 | 44 | 17 | |
2 | 2 | 2 | 2 | 2 | 0 | ||||||||||
S2414-NSCLC, Stg II-IIIB, Durva vs Surveillance | LUNG | SXQOL | 306 | 1 | Y | 1 Durvalumab | 1 | 1 | 1 | 1 | 0 | 0 | 04/01/2025 | 128 | 30 |
1 | 1 | 1 | 1 | 0 | 0 | ||||||||||
A011801-BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib | BREAST | SXQOL | 1 | E | 55 | 11 | 8 | 2 | 0 | 0 | 03/11/2021 | 435 | 206 | ||
55 | 11 | 8 | 2 | 0 | 0 | ||||||||||
A012103-Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab | BREAST | SXQOL | 1 | E | 25 | 18 | 13 | 8 | 3 | 1 | 08/24/2023 | 367 | 183 | ||
25 | 18 | 13 | 8 | 3 | 1 | ||||||||||
A021806-Pancreas, Perioperative vs Adjuvant Chemo | GI | SXQOL | 0 | E | 41 | 5 | 4 | 2 | 1 | 0 | 10/08/2020 | 273 | 115 | ||
41 | 5 | 4 | 2 | 1 | 0 | ||||||||||
1 | E | 33 | 3 | 2 | 1 | 0 | 0 | ||||||||
33 | 3 | 2 | 1 | 0 | 0 | ||||||||||
A032103-Urothelial, All Stg, MRD-Based Adj Tx | GU | SXQOL | 0 | E | 26 | 25 | 22 | 13 | 3 | 0 | 03/19/2024 | 344 | 137 | ||
26 | 25 | 22 | 13 | 3 | 0 | ||||||||||
1 | E | 19 | 18 | 17 | 12 | 5 | 1 | ||||||||
19 | 18 | 17 | 12 | 5 | 1 | ||||||||||
2 | E | 2 | 2 | 2 | 2 | 2 | 0 | ||||||||
2 | 2 | 2 | 2 | 2 | 0 | ||||||||||
A052101-Lymph, Stg I-IV, Cont v Intermittent Zanub | LYMPH | SXQOL | 1 | E | 17 | 12 | 5 | 1 | 0 | 0 | 01/03/2024 | 200 | 69 | ||
17 | 12 | 5 | 1 | 0 | 0 | ||||||||||
2 | E | 9 | 8 | 6 | 4 | 0 | 0 | ||||||||
9 | 8 | 6 | 4 | 0 | 0 | ||||||||||
A081801-ALCHEMIST4, ALK and EGFR negative, Chemo-IO | LUNG | SXQOL | 1 | E | 92 | 16 | 5 | 5 | 2 | 0 | 10/20/2020 | 422 | 173 | ||
92 | 16 | 5 | 5 | 2 | 0 | ||||||||||
A211901-Cancer survivors who smoke, txt cessation | SXQOL | 1 | E | 14 | 8 | 1 | 1 | 1 | 1 | 09/12/2023 | 137 | 51 | |||
14 | 8 | 1 | 1 | 1 | 1 | ||||||||||
ACCL16N1-Guideline Consistent Treatment AYA ALL | CCD | 1 | T | 54 | 0 | 0 | 0 | 0 | 0 | 10/24/2018 | |||||
54 | 0 | 0 | 0 | 0 | 0 | ||||||||||
AHOD2131-cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy | LYMPH | SXQOL | 1 | E | 51 | 34 | 21 | 14 | 2 | 0 | 08/15/2023 | 272 | 128 | ||
51 | 34 | 21 | 14 | 2 | 0 | ||||||||||
2 | E | 42 | 29 | 19 | 13 | 6 | 2 | ||||||||
42 | 29 | 19 | 13 | 6 | 2 | ||||||||||
CCTGHN11-HN, All Stg, Guided Elec Contra Neck Tx | OTHER | SXQOL | 1 | E | 1 | 0 | 0 | 0 | 0 | 0 | 02/07/2024 | 87 | 22 | ||
1 | 0 | 0 | 0 | 0 | 0 | ||||||||||
2 | E | 1 | 0 | 0 | 0 | 0 | 0 | ||||||||
1 | 0 | 0 | 0 | 0 | 0 | ||||||||||
EA5221-Lung, Advanced NSCLC, ChemoImmuno/Immuno | LUNG | SXQOL | 1 | E | 3 | 3 | 2 | 1 | 0 | 0 | 08/07/2024 | 190 | 74 | ||
3 | 3 | 2 | 1 | 0 | 0 | ||||||||||
2 | E | 2 | 2 | 1 | 0 | 0 | 0 | ||||||||
2 | 2 | 1 | 0 | 0 | 0 | ||||||||||
EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) | MMYEL | SXQOL | 0 | E | 54 | 8 | 4 | 3 | 1 | 0 | 05/27/2021 | 229 | 78 | ||
54 | 8 | 4 | 3 | 1 | 0 | ||||||||||
1 | E | 40 | 5 | 3 | 3 | 1 | 0 | ||||||||
40 | 5 | 3 | 3 | 1 | 0 | ||||||||||
2 | E | 29 | 12 | 3 | 0 | 0 | 0 | ||||||||
29 | 12 | 3 | 0 | 0 | 0 | ||||||||||
EAQ211-Lymph, Survivors, Health Disp. AYA | SURV | 1 | E | 3 | 3 | 3 | 2 | 0 | 0 | 12/24/2024 | |||||
3 | 3 | 3 | 2 | 0 | 0 | ||||||||||
EAQ222CD-CostCOM, Cancer Patients, OOP Cost Com | CCD | 0 | E | 19 | 19 | 14 | 8 | 3 | 1 | 08/27/2024 | 41 | 19 | |||
19 | 19 | 14 | 8 | 3 | 1 | ||||||||||
1 | E | 15 | 15 | 11 | 6 | 0 | 0 | ||||||||
15 | 15 | 11 | 6 | 0 | 0 | ||||||||||
MA39-BREAST, Node-Pos, Reg RT vs No Reg RT | BREAST | SXQOL | 1 | E | 55 | 26 | 13 | 11 | 2 | 0 | 10/18/2019 | 378 | 150 | ||
55 | 26 | 13 | 11 | 2 | 0 | ||||||||||
2 | E | 53 | 25 | 12 | 10 | 2 | 0 | ||||||||
53 | 25 | 12 | 10 | 2 | 0 | ||||||||||
NRGCC010-Endo, Stg I, LN Map for LE Limb Dysfunction | SXQOL | OTHER | 1 | E | 14 | 6 | 1 | 1 | 1 | 0 | 12/07/2022 | 70 | 25 | ||
14 | 6 | 1 | 1 | 1 | 0 | ||||||||||
NRGCC011-Breast, Survivors, Cog Training | SXQOL | 0 | E | 50 | 49 | 17 | 8 | 3 | 0 | 04/03/2024 | 247 | 95 | |||
50 | 49 | 17 | 8 | 3 | 0 | ||||||||||
1 | E | 34 | 33 | 13 | 6 | 1 | 0 | ||||||||
34 | 33 | 13 | 6 | 1 | 0 | ||||||||||
NRGGU008-Pros,Node+, Abiraterone acetate + Apalutamide | GU | SXQOL | 1 | E | 14 | 1 | 0 | 0 | 0 | 0 | 09/25/2020 | 285 | 97 | ||
14 | 1 | 0 | 0 | 0 | 0 | ||||||||||
NRGGU011-Pros, Dbl Blinded RT +/- Androgen Dep Tx | GU | SXQOL | 1 | E | 17 | 8 | 6 | 4 | 0 | 0 | 03/29/2023 | 244 | 85 | ||
17 | 8 | 6 | 4 | 0 | 0 | ||||||||||
NRGLU008-Lung NSCL, StgII-III, StereoBodyRad/MedChemo | LUNG | SXQOL | 1 | E | 3 | 2 | 1 | 1 | 1 | 0 | 01/26/2024 | 298 | 116 | ||
3 | 2 | 1 | 1 | 1 | 0 | ||||||||||
A012301-Breast, Early Stg, Tamoxifen | BREAST | SXQOL | 1 | E | 2 | 2 | 2 | 2 | 0 | 0 | 03/07/2025 | 291 | 71 | ||
2 | 2 | 2 | 2 | 0 | 0 | ||||||||||
A031801-GU, mRCC, Cabozantinib ± Radium-223 | GU | SXQOL | 1 | E | 15 | 1 | 0 | 0 | 0 | 0 | 11/06/2020 | 112 | 39 | ||
15 | 1 | 0 | 0 | 0 | 0 | ||||||||||
A082002-Lung, Adv, Systemic Tx +/- SBRT | LUNG | SXQOL | 1 | E | 4 | 0 | 0 | 0 | 0 | 0 | 10/12/2022 | 241 | 68 | ||
4 | 0 | 0 | 0 | 0 | 0 | ||||||||||
A191901-Brst, Text/Motivational Intervention ET Adher | CCD | 1 | E | 42 | 3 | 2 | 1 | 0 | 0 | 06/14/2021 | 178 | 86 | |||
42 | 3 | 2 | 1 | 0 | 0 | ||||||||||
A212102-Blind Ref Set for Multicancer Early Detection | PREV | 1 | E | 210 | 113 | 48 | 32 | 5 | 0 | 11/28/2022 | 189 | 90 | |||
210 | 113 | 48 | 32 | 5 | 0 | ||||||||||
A222004-Mult, Olanza vs Megestrol for Anorexia | SXQOL | 1 | E | 7 | 4 | 0 | 0 | 0 | 0 | 03/17/2022 | 54 | ||||
7 | 4 | 0 | 0 | 0 | 0 | ||||||||||
A231602C-Blood Cancer, Assess Financial Difficulty | CCD | 1 | T | 4 | 0 | 0 | 0 | 0 | 0 | 06/04/2020 | |||||
4 | 0 | 0 | 0 | 0 | 0 | ||||||||||
ACCL1931-Leuk, All Stg, Levocarnitine Prophylaxis | SXQOL | 1 | E | 4 | 2 | 2 | 2 | 0 | 0 | 03/29/2024 | 153 | 71 | |||
4 | 2 | 2 | 2 | 0 | 0 | ||||||||||
2 | E | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||
0 | 0 | 0 | 0 | 0 | 0 | ||||||||||
AGCT1531-Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult | ERLYTX | SXQOL | 1 | E | 3 | 1 | 1 | 1 | 0 | 0 | 10/07/2021 | 189 | 118 | ||
3 | 1 | 1 | 1 | 0 | 0 | ||||||||||
2 | E | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||
0 | 0 | 0 | 0 | 0 | 0 | ||||||||||
AGCT1532-Inter/Poor Met GCTs, Accel v Std BEP Chemo | OTHER | SXQOL | 1 | T | 5 | 1 | 1 | 0 | 0 | 0 | 12/13/2019 | 168 | 91 | ||
5 | 1 | 1 | 0 | 0 | 0 | ||||||||||
CCTGCO32-Rectal, Early Stg, Neoadj/Exc/Obs vs ChemRad | GI | SXQOL | 1 | E | 5 | 5 | 2 | 2 | 1 | 0 | 06/26/2024 | 127 | 46 | ||
5 | 5 | 2 | 2 | 1 | 0 | ||||||||||
CCTGNE1-Midgut NET, Unresect, 177 Lut vs Ever | GI | SXQOL | 1 | E | 4 | 4 | 1 | 0 | 0 | 0 | 06/11/2024 | 58 | 16 | ||
4 | 4 | 1 | 0 | 0 | 0 | ||||||||||
CE7-Brain, 5+ Metastases, Radiosurg/Radiotherapy | OTHER | SXQOL | 1 | E | 1 | 1 | 0 | 0 | 0 | 0 | 06/17/2024 | 110 | 41 | ||
1 | 1 | 0 | 0 | 0 | 0 | ||||||||||
2 | E | 1 | 1 | 0 | 0 | 0 | 0 | ||||||||
1 | 1 | 0 | 0 | 0 | 0 | ||||||||||
EA2185-Panc, Impact of Panc Cyst Surveillance | PREV | SXQOL | 1 | E | 19 | 0 | 0 | 0 | 0 | 0 | 03/03/2021 | 128 | 73 | ||
19 | 0 | 0 | 0 | 0 | 0 | ||||||||||
EA8134-Penile, Local Adv, ILND +/- Chemo or ChemoRT | GU | SXQOL | 1 | E | 16 | 4 | 3 | 2 | 1 | 0 | 04/25/2019 | 42 | 16 | ||
16 | 4 | 3 | 2 | 1 | 0 | ||||||||||
2 | E | 1 | 1 | 1 | 1 | 1 | 0 | ||||||||
1 | 1 | 1 | 1 | 1 | 0 | ||||||||||
EA8184-Pros, Dbl Blind GTC vs Placebo | PREV | SXQOL | 0 | E | 28 | 14 | 5 | 2 | 0 | 0 | 08/24/2022 | 103 | 45 | ||
28 | 14 | 5 | 2 | 0 | 0 | ||||||||||
1 | E | 12 | 7 | 3 | 2 | 0 | 0 | ||||||||
12 | 7 | 3 | 2 | 0 | 0 | ||||||||||
EA8191-Pros, Local vs Systemic Thrpy | GU | SXQOL | 0 | E | 65 | 30 | 11 | 0 | 0 | 0 | 09/24/2021 | 193 | 62 | ||
65 | 30 | 11 | 0 | 0 | 0 | ||||||||||
1 | E | 65 | 30 | 11 | 0 | 0 | 0 | ||||||||
65 | 30 | 11 | 0 | 0 | 0 | ||||||||||
EA8212-Blad, NMIBC, BRIDGE | GU | SXQOL | 1 | E | 234 | 126 | 64 | 35 | 14 | 2 | 02/07/2023 | 168 | 79 | ||
234 | 126 | 64 | 35 | 14 | 2 | ||||||||||
EAA173-MYEL, SMM, Rd +/- Daratumumab | MMYEL | SXQOL | 0 | E | 76 | 9 | 2 | 1 | 1 | 1 | 01/08/2020 | 252 | 100 | ||
76 | 9 | 2 | 1 | 1 | 1 | ||||||||||
1 | E | 37 | 8 | 2 | 0 | 0 | 0 | ||||||||
37 | 8 | 2 | 0 | 0 | 0 | ||||||||||
EAQ202-Improving AYA PROs in EA Trials | SXQOL | 1 | E | 43 | 0 | 0 | 0 | 0 | 0 | 12/13/2021 | 42 | 22 | |||
43 | 0 | 0 | 0 | 0 | 0 | ||||||||||
EAQ221CD-Breast, Metastatic, Imp. Adherence | CCD | 0 | E | 2 | 2 | 2 | 1 | 0 | 0 | 01/13/2025 | 141 | 49 | |||
2 | 2 | 2 | 1 | 0 | 0 | ||||||||||
1 | E | 2 | 2 | 2 | 1 | 0 | 0 | ||||||||
2 | 2 | 2 | 1 | 0 | 0 | ||||||||||
NRGBN003-Mening, Grd II, Observation vs Irradiation | OTHER | SXQOL | 1 | E | 5 | 0 | 0 | 0 | 0 | 0 | 06/24/2019 | 282 | 85 | ||
5 | 0 | 0 | 0 | 0 | 0 | ||||||||||
2 | E | 3 | 0 | 0 | 0 | 0 | 0 | ||||||||
3 | 0 | 0 | 0 | 0 | 0 | ||||||||||
NRGBN011-Brain, Lomustine + Temo vs Temo | OTHER | SXQOL | 1 | E | 38 | 21 | 9 | 5 | 1 | 1 | 07/18/2022 | 302 | 112 | ||
38 | 21 | 9 | 5 | 1 | 1 | ||||||||||
2 | E | 11 | 7 | 3 | 0 | 0 | 0 | ||||||||
11 | 7 | 3 | 0 | 0 | 0 | ||||||||||
NRGBN012-Brain, Pre- vs Post-Op Stereotactic Radiosurg | OTHER | SXQOL | 1 | E | 4 | 3 | 0 | 0 | 0 | 0 | 05/30/2023 | 238 | 96 | ||
4 | 3 | 0 | 0 | 0 | 0 | ||||||||||
NRGBR007-Breast, Stg I, De-Escalation of Breast RT | BREAST | SXQOL | 1 | E | 24 | 16 | 12 | 6 | 0 | 0 | 06/01/2022 | 402 | 176 | ||
24 | 16 | 12 | 6 | 0 | 0 | ||||||||||
2 | E | 22 | 14 | 10 | 6 | 0 | 0 | ||||||||
22 | 14 | 10 | 6 | 0 | 0 | ||||||||||
NRGBR008-Breast, LowRisk HER2+, Radiotherapy | BREAST | SXQOL | 1 | E | 1 | 1 | 1 | 1 | 0 | 0 | 03/10/2025 | 1 | 1 | ||
1 | 1 | 1 | 1 | 0 | 0 | ||||||||||
NRGBR009-Breast, EarlyStg, Adjuvant Chemo | BREAST | SXQOL | 1 | E | 13 | 10 | 6 | 4 | 2 | 0 | 01/31/2024 | 447 | 189 | ||
13 | 10 | 6 | 4 | 2 | 0 | ||||||||||
2 | E | 13 | 10 | 7 | 4 | 2 | 0 | ||||||||
13 | 10 | 7 | 4 | 2 | 0 | ||||||||||
NRGCC005-Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs | PREV | 1 | E | 70 | 66 | 45 | 28 | 12 | 1 | 12/05/2023 | 192 | 81 | |||
70 | 66 | 45 | 28 | 12 | 1 | ||||||||||
NRGCC008-Ovar, BRCA1, non-inferiority of BLS vs BSO | PREV | SXQOL | 1 | E | 12 | 3 | 1 | 1 | 1 | 0 | 04/08/2021 | 321 | 137 | ||
12 | 3 | 1 | 1 | 1 | 0 | ||||||||||
NRGGI006-Esophagus, Stg I-IVA, PBT vs IMRT | GI | SXQOL | 1 | E | 1 | 1 | 0 | 0 | 0 | 0 | 06/21/2024 | 20 | 4 | ||
1 | 1 | 0 | 0 | 0 | 0 | ||||||||||
2 | E | 1 | 1 | 0 | 0 | 0 | 0 | ||||||||
1 | 1 | 0 | 0 | 0 | 0 | ||||||||||
NRGGU009-Pros, PREDICT-RT | GU | SXQOL | 1 | E | 92 | 36 | 7 | 1 | 0 | 0 | 03/01/2022 | 463 | 171 | ||
92 | 36 | 7 | 1 | 0 | 0 | ||||||||||
2 | E | 85 | 35 | 5 | 1 | 0 | 0 | ||||||||
85 | 35 | 5 | 1 | 0 | 0 | ||||||||||
NRGGU010-Pros, Parallel De-Intens & Intens Trials | GU | SXQOL | 1 | E | 67 | 30 | 6 | 0 | 0 | 0 | 01/03/2022 | 470 | 172 | ||
67 | 30 | 6 | 0 | 0 | 0 | ||||||||||
2 | E | 62 | 29 | 8 | 0 | 0 | 0 | ||||||||
62 | 29 | 8 | 0 | 0 | 0 | ||||||||||
NRGGU013-Prostate, High-Risk, Five Fraction Radiation | GU | SXQOL | 1 | E | 8 | 8 | 3 | 3 | 1 | 0 | 05/28/2024 | 228 | 90 | ||
8 | 8 | 3 | 3 | 1 | 0 | ||||||||||
NRGGY026-Endomet, Stage I-IV, Pac/Car w/ HER HYL/PHE | OTHER | SXQOL | 1 | E | 1 | 1 | 0 | 0 | 0 | 0 | 05/28/2024 | 317 | 129 | ||
1 | 1 | 0 | 0 | 0 | 0 | ||||||||||
NRGHN006-HN, Erly Stg, Biopsy vs Dissection | OTHER | SXQOL | 1 | E | 3 | 2 | 0 | 0 | 0 | 0 | 08/06/2021 | 221 | 73 | ||
3 | 2 | 0 | 0 | 0 | 0 | ||||||||||
2 | E | 3 | 1 | 0 | 0 | 0 | 0 | ||||||||
3 | 1 | 0 | 0 | 0 | 0 | ||||||||||
NRGHN009-HN, RT + HD Cisp vs RT + LD Cisp for SCCHN | OTHER | SXQOL | 1 | E | 18 | 4 | 1 | 1 | 0 | 0 | 03/15/2022 | 284 | 113 | ||
18 | 4 | 1 | 1 | 0 | 0 | ||||||||||
R1216-HN, Adv,Cis vs Dtx vs Dtx+Cetux | OTHER | SXQOL | 1 | E | 7 | 1 | 1 | 0 | 0 | 0 | 07/24/2015 | 353 | 111 | ||
7 | 1 | 1 | 0 | 0 | 0 | ||||||||||
2 | E | 6 | 1 | 1 | 0 | 0 | 0 | ||||||||
6 | 1 | 1 | 0 | 0 | 0 | ||||||||||
Study | Admin | CCAdmin | Registration/Phase | Open Date |
---|---|---|---|---|
ACCL1931 Leuk, All Stg, Levocarnitine Prophylaxis | SXQOL | 2 Callback | 14-Aug-23 | |
AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult | ERLYTX | SXQOL | 2 Late Randomization Callback | 08-May-17 |